Literature DB >> 34142007

Necrotizing myopathy presenting as congestive heart failure and life-threatening ventricular arrhythmias: a case report.

Kyunghee Lim1, Jong Sung Park1, Byeol-A Yoon2, Song-Hee Han3.   

Abstract

BACKGROUND: Necrotizing autoimmune myopathy is a rare subtype of idiopathic inflammatory myopathy; however, it can be associated with fatal cardiac manifestations. CASE
SUMMARY: A 58-year-old female patient was referred for congestive heart failure with dysrhythmia. Electrocardiograms showed ventricular arrhythmias of various QRS complex morphologies and coupling intervals with beat-to-beat differences. Despite optimal medical therapy for heart failure, the patient was admitted for the progression of dyspnoea and generalized motor weakness. The burden of non-sustained ventricular tachycardia gradually increased, and ventricular fibrillation eventually occurred. In view of a differential diagnosis of an inflammatory myocardial diseases such as sarcoidosis, a cardiac biopsy was performed. However, pathologic examinations revealed only necrotic muscle fibres without granuloma. Further examinations revealed proximal dominant motor weakness, an elevated serum creatinine-phosphokinase level, myogenic potentials on needle electromyography, and biceps muscle biopsy findings that were compatible with necrotizing autoimmune myopathy. High-dose steroid therapy improved the patient's motor weakness, including her respiratory impairment, and successfully suppressed ventricular arrhythmias. DISCUSSION: This case suggests that intensive immunosuppressive therapy with high-dose steroid could be useful in the necrotizing autoimmune myopathy manifested as congestive heart failure and life-threatening ventricular arrhythmias.
© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.

Entities:  

Keywords:  Cardiac arrhythmia; Case report; Heart failure; Necrotizing myopathy

Year:  2021        PMID: 34142007      PMCID: PMC8207167          DOI: 10.1093/ehjcr/ytab075

Source DB:  PubMed          Journal:  Eur Heart J Case Rep        ISSN: 2514-2119


Learning points Cardiac involvement of necrotizing autoimmune myopathy should be considered as a possible cause of congestive heart failure and life-threatening ventricular arrhythmias. Complications of necrotizing autoimmune myopathy including arrhythmias may be successfully controlled by aggressive immune suppressive therapy, such as high-dose steroid.

Introduction

Necrotizing autoimmune myopathy is a rare subtype of idiopathic inflammatory myopathy comprising polymyositis and dermatomyositis. Although mild arrhythmias, such as premature ventricular contractions or non-specific conduction abnormalities, have been the most common electrocardiographic findings observed in approximately 30% of affected patients, cases of life-threatening ventricular arrhythmias have been rarely reported. We report a case of necrotizing autoimmune myopathy manifesting as congestive heart failure and life-threatening ventricular arrhythmias which were controlled with high-dose steroid therapy. Observed polymorphic ventricular tachycardia degenerated into ventricular fibrillation, requiring defibrillated. Echocardiography revealed a decreased ejection fraction of 37% with an akinetic basal septum. Patient administered with pulse intravenous methylprednisolone 125 mg once. Because of high fever over 38.3°C, high-dose steroid treatment was discontinued. N-terminal pro-brain natriuretic peptide 10 140.0 pg/ml (normal range: <287 pg/ml) Needle electromyography and nerve conduction study suggestive of myopathy. Low-dose hydrocortisone treatment initiated. Bicep muscle biopsy confirmed autoimmune necrotizing myopathy. Gradual improvement in motor power and respiratory muscle weakness. Patient weaned off mechanical ventilator support. Gradual return of cardiac rhythm and improvement in daily burden of ventricular arrhythmia in 24-h ambulatory ECG monitoring (<10%). Patient discharged from hospital.

Case presentation

A 58-year-old woman was referred to our institution for the evaluation of progressive dyspnoea, dizziness, and general weakness. Initial standard 12-lead electrocardiogram (ECG) showed diffuse intracardiac conduction abnormalities (). The patient’s medical history was unremarkable. A chest X-ray image showed marked cardiomegaly with bilateral pleural effusions. Echocardiography demonstrated a dilated left ventricle with preserved ejection fraction [left ventricular (LV) end-diastolic volume 160 mL; LV end-systolic volume 71 mL; LV ejection fraction 55%] and grade II diastolic dysfunction with elevated left atrial pressure [ratio of peak early to late diastolic filling velocity (E/A ratio) 1.5; ratio of mitral peak velocity of early filling (E) to early diastolic mitral annular velocity (E′) (E/E′ ratio) 18.9; left atrial volume index 47.5 mL/m2]. Twenty-four-hour ambulatory ECG monitoring revealed the recurrence of sustained atrial fibrillation. Under the impression of heart failure with a preserved ejection fraction and paroxysmal atrial fibrillation, the patient was treated with losartan 50 mg/day, furosemide 40 mg/day, and spironolactone 25 mg/day for over 5 months. However, her symptoms gradually aggravated, and multifocal ventricular arrhythmias were observed on follow-up ECGs (). Bisoprolol 2.5 mg/day or amiodarone 200 mg/day maintenance therapy failed to suppress the recurrence of ventricular premature beats or atrial fibrillation and was discontinued due to the development of severe sinus bradycardia with dizziness. Finally, the patient was admitted for aggravation of dyspnoea and a sensation of general weakness. Electrocardiographic findings. (A) Initial standard 12-lead ECG showed small P waves (red arrows) less than 0.1 mV and prolonged PR intervals of 220 ms. Diffuse intraventricular conduction delay with left bundle branch block-like QRS complex morphology, QRS complex duration of 140 ms, and left axis deviation were noted. Broad U waves (blue arrow) of 200 ms and prolongation of QT intervals were also noted. Initial ECG findings suggested the presence of a diffuse conduction disorder involving both atriums and ventricles. (B) Follow-up standard 12-lead ECG recorded after aggravation of congestive heart failure showed abnormal ventricular depolarizations (stars) of left bundle branch configurations in the V1 lead, suggestive of a left ventricular origin. Abnormal depolarizations had various QRS complex morphologies and coupling intervals with beat-to-beat differences reflecting their multifocal origins due to increased automaticity. Abnormal ventricular depolarizations raised the suspicion of myocardial disease. (C) Telemetry recordings revealed the onset of R-on-T phenomenon in atrial fibrillation at the ventricular rates of 70–90 beat per minute (b.p.m.) followed by polymorphic VT. Polymorphic VT degenerated into VF which was terminated by external defibrillation (empty arrow). Although no inotropic agent was administered after termination of VF, VT with various QRS complex morphologies was sustained for 1 min, suggestive of increased automaticity as its electrophysiologic mechanism. (D) A 24-h ambulatory ECG monitoring before high-dose steroid therapy showed frequent episodes of non-sustained VT of 150 b.p.m. The daily burden of ventricular arrhythmia was 30–40%. b.p.m., beat per minute; ECG, electrocardiogram; VF, ventricular fibrillation; VT, ventricular tachycardia. Continued Continued The patient complained of New York Heart Association class IV dyspnoea. Although minimal lower extremity pitting oedema was noted on physical examination, typical signs of heart failure such as pulmonary crackles and internal jugular vein distention were not prominent. Cardiac biomarker studies revealed marked increases in N-terminal pro-brain natriuretic peptide of 10 140 (reference: 0–287) pg/mL, troponin-I of 0.2035 (reference: 0–0.0156) ng/mL, and creatinine phosphokinase of 437 (reference: 0–145) U/L. Antinuclear antibody titer was 1:160 (reference: negative). Although the patient received high-dose furosemide for pulmonary decongestion over a period of 4 days, she required intubation for respiratory acidosis and drowsiness. One day after the initiation of mechanical ventilation, the R-on-T phenomenon began to appear on ECG monitoring at a serum potassium concentration of 3.9 (3.5–5.1) mEq/L in atrial fibrillation at a rate of 70–90 beats per minute. Eventually, polymorphic ventricular tachycardia (VT) degenerated into ventricular fibrillation (VF), and the patient was defibrillated (). Unlike conventional acquired long QT syndrome induced by hypokalaemia, non-sustained VTs with various QRS complex morphologies with beat-to-beat differences recurred, frequently, even after the correction of serum potassium concentrations to over 5.3 mEq/L (). Echocardiography showed a decreased ejection fraction of 37% with an akinetic basal septum ( and B, Videos 1 and 2). However, coronary angiography showed no stenotic lesions. Under the impression of inflammatory myocardial disease such as sarcoidosis, methyl-prednisolone 125 mg was infused once to prevent the recurrence of polymorphic VT or VF. However, 1 day after methyl-prednisolone administration, a high fever of over 38°C developed and persisted for a total of 2 weeks, although all subsequent laboratory test findings were unremarkable. Broad spectrum empirical antibiotics were administered considering the possibility of infection. Because the recurrence of non-sustained VTs was remarkably reduced after a single infusion of high-dose methyl-prednisolone, endomyocardial biopsy was performed to confirm the diagnosis of inflammatory myocardial disease. However, pathologic examinations showed non-specific inflammatory changes with regeneration (). Tracheostomy was performed to maintain mechanical ventilation. Cardiac magnetic resonance imaging study has been attempted several times, but it could not be performed due to severe respiratory muscle weakness. 18F-fluorodeoxyglucose positron-emission tomography/computed tomography scan did not show abnormal myocardial uptake (). We could not make a clinical diagnosis to explain the occurrence of polymorphic VT and pleomorphic non-sustained VT for more than 4 weeks. Findings of multimodality cardiac imaging studies. Echocardiograms taken 1 day after cardiac arrest in the apical four-chamber view of the end-diastole (A) and end-systole (B) showed a decreased LV ejection fraction of 37% with an akinetic basal septum (arrow) and dilated LV. Maximum-intensity projection image (C) and fused 8F-FDG positron-emission tomography/computed tomography image (D) showed no abnormal FDG uptake in the LV myocardium. FDG, fluorodeoxyglucose; LV, left ventricular. Pathologic findings of cardiac and biceps muscle biopsy specimens. (A) Haematoxylin and eosin staining of the cardiac biopsy specimen showed focal infiltrates of inflammatory cells (solid arrow), the formation of fibrosis, and myocardial regenerative changes (dotted arrows), suggesting the possibility of myocardial inflammation. (B) Haematoxylin and eosin staining of the specimen from the biceps muscle biopsy showed various-sized muscle fibres, reflecting skeletal muscle atrophy, and a necrotic muscle fibre (black arrow) without remarkable infiltration of inflammatory cells. (C) Acid phosphatase stained section of the specimen from the biceps muscle biopsy showed mild phosphatase activation, reflecting necrotized muscle fibres (black arrows). Fortuitously, prolonged ventilator weaning failure with unexplained respiratory muscle weakness in the absence of pulmonary oedema or other active lung disease on chest imaging studies raised a clinical suspicion of systemic myopathy. During a bedside swallowing study, dysphagia was observed. Aggravation of dysphagia and progressive weakness of the upper and lower extremities along with a Medical Research Council score of 3/5 also supported the possibility of systemic myopathy. Needle electromyography demonstrated fibrillation potentials and small-amplitude, short-duration motor unit action potentials as well as increased recruitment in the upper and lower extremity muscles. Nerve conduction study findings were unremarkable. Biceps muscle biopsy revealed necrotic muscle fibres without significant inflammatory infiltrates, findings consistent with necrotizing autoimmune myopathy (). We therefore administered immune suppressive therapy. The patient received oral prednisolone 10–20 mg/day for 2 months in combination with human immunoglobulin G (2 g/kg for 3 days, 2 cycles) or methotrexate (2.5–12.5 mg/week) therapy, and maintenance therapy allowed improvement of her respiratory muscle power until she was completely weaned off the ventilator. However, non-sustained monomorphic VT frequently recurred (). Although low-dose amiodarone or sotalol maintenance therapy was considered, due to a prior history of severe bradycardia and risk of polymorphic VT recurrence, we decided to continue immune suppressive therapy. Fortunately, high-dose steroid therapy (dexamethasone 10 mg/day infusion for 7 days followed by oral prednisolone 20 mg/day) successfully suppressed the recurrence of non-sustained monomorphic VT with a marked reduction in the daily burden of ventricular premature beat (). Because the patient strongly refused implantable cardioverter-defibrillator implantation to prevent sudden arrhythmic death against medical recommendation, we continued prolonged ECG monitoring for the recurrence of polymorphic or sustained pleomorphic VT until discharge. The patient was discharged on methotrexate and oral prednisolone combination therapy after improvements in dyspnoea and general weakness at 38 weeks after admission. During the follow-up duration over 1 year, the patient’s functional status was well preserved with New York Heart Association class II dyspnoea and Medical Research Council score 5/5 motor power. Although occasional recurrences of slow monomorphic VT of 1–2 s were observed on repeated ambulatory ECG monitoring, there were no further recurrences of polymorphic or sustained pleomorphic VTs. Ventricular premature beat burden with immunotherapy. Bar graph represents the change in daily ventricular premature beat burden recorded by monthly 24-h ambulatory electrocardiographic monitoring after the patient’s first visit.

Discussion

Necrotizing autoimmune myopathy is a rare subtype of idiopathic inflammatory myopathy with the unique features of subacute proximal limb weakness, increased serum creatinine phosphokinase levels, myopathic electromyographic findings, and a muscle biopsy demonstrating necrotic muscle fibres with minimal inflammatory infiltration. Although cardiac arrhythmias associated with idiopathic inflammatory myopathies have been reported in up to 2.4–13.8% of cases, most have been reported as benign conduction disorders. According to a systematic review of inflammatory myopathies with cardiac involvement, complete heart block has been suggested as the cause of cardiac deaths in approximately 10% of cases. Non-specific arrhythmias were also reported as the cause of cardiac death in approximately 8% of cases. It appears that cardiac arrhythmia complicating inflammatory myopathies often results in fatal clinical outcomes. Interestingly, in the present case, various arrhythmias from a diffuse conduction disorder through atrial fibrillation to monomorphic and polymorphic VTs appeared in accordance with the disease progression. Morphologic features of ventricular premature beats and VTs suggested increased automaticity as their electrophysiologic mechanism and raised a clinical suspicion of inflammatory myocardial diseases, such as isolated cardiac sarcoidosis. However, a cardiac biopsy did not show any specific findings. Systemic myopathies were not considered until the patient suffered a prolonged ventilator weaning failure. Clinical manifestations of the patient emphasize that necrotizing autoimmune myopathy may present as various atrial and ventricular arrhythmias that cannot be explained by known arrhythmic or structural heart diseases, which can present as heart failure. Necrotizing autoimmune myopathy is known to be refractory to conventional immunotherapy. Although a standard therapy protocol has not yet been established, an aggressive combination immune-suppressive therapy has been recommended, especially in cases with cardiac complications. In the present case, although low-dose steroid or human immunoglobulin and methotrexate combination therapy failed, high-dose steroid therapy successfully suppressed the recurrence of VTs and the daily burden of ventricular premature beat. Although clinical evidence is limited, our case suggests that aggressive immune suppressive therapy may, at least partially, elicit antiarrhythmic effects in patients with necrotizing autoimmune myopathy. In this patient, we considered defibrillator implantation before discharge for the secondary prevention of sudden arrhythmic death. However, the patient strongly refused any further invasive procedures, including defibrillator implantation. We were also unsure whether defibrillator therapy would impart a survival benefit because the risk of non-cardiac death by respiratory failure or infection was expected to be high at the time of admission. Defibrillator therapy is now under consideration as a therapeutic option because the clinical response to steroid therapy has been satisfactory and the patient’s functional status has been well preserved.

Lead author biography

Kyunghee Lim is currently an Assistant Professor of Cardiology at Dong-A University Hospital. She graduated from Dong-A University in 2012. She became resident in Samsung Medical Center from 2013 to 2017 in internal medicine, and then a fellow in cardiology, Samsung Medical Center from 2018 to 2019. She is interested in clinical cardiology and echocardiography.

Supplementary material

Supplementary material is available at European Heart Journal - Case Reports online. Slide sets: A fully edited slide set detailing this case and suitable for local presentation is available online as Supplementary data. Consent: The authors confirm that written informed consent for submission and publication of this case report including images and associated text has been obtained from the patient in line with COPE guidance. Conflict of interest: None declared. Funding: None declared. Click here for additional data file.
TimeEvents
4 months prior to admissionDyspnoea on exertion, dizziness, and general weakness.
3 months prior to admissionFirst visit to medical centre, angiotensin II receptor blocker, beta blocker, diuretics, and spironolactone treatment were initiated under the impression of heart failure. Twenty-four hour ambulatory electrocardiogram (ECG) monitoring: daily burden of ventricular arrhythmia 20–30%.
2 months prior to admissionAtrial fibrillation observed.
First day of admissionAcute decompensated heart failure with pleural effusion observed and treated with additional diuretics. Creatine kinase level 919 U/L (normal range: 0–145 U/L).
Second admission (day of admission)After 1 month, patient was readmitted for aggravated dyspnoea and general weakness.
Day 5 of admissionMechanical ventilator used due to respiratory acidosis and drowsiness.

Observed polymorphic ventricular tachycardia degenerated into ventricular fibrillation, requiring defibrillated.

Echocardiography revealed a decreased ejection fraction of 37% with an akinetic basal septum. Patient administered with pulse intravenous methylprednisolone 125 mg once. Because of high fever over 38.3°C, high-dose steroid treatment was discontinued.

N-terminal pro-brain natriuretic peptide 10 140.0 pg/ml (normal range: <287 pg/ml)

2 weeks after admissionEndomyocardial biopsy performed.
3 weeks after admissionTracheostomy performed.
10 weeks after admission 18F-Fluorodeoxyglucose positron-emission tomography/computed tomography scan performed and did not show abnormal myocardial uptake.
11 weeks after admission

Needle electromyography and nerve conduction study suggestive of myopathy.

Low-dose hydrocortisone treatment initiated.

15 weeks after admission

Bicep muscle biopsy confirmed autoimmune necrotizing myopathy.

Gradual improvement in motor power and respiratory muscle weakness.

Patient weaned off mechanical ventilator support.

22 weeks after admissionIntravenous immunoglobulin G, methotrexate treatment initiated.
31 weeks after admissionPatient administered with daily pulse intravenous dexamethasone for 1 week followed by tapering doses of oral prednisolone.
38 weeks after admission

Gradual return of cardiac rhythm and improvement in daily burden of ventricular arrhythmia in 24-h ambulatory ECG monitoring (<10%).

Patient discharged from hospital.

  10 in total

1.  119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands.

Authors:  Jessica E Hoogendijk; Anthony A Amato; Bryan R Lecky; Ernest H Choy; Ingrid E Lundberg; Michael R Rose; Jiri Vencovsky; Marianne de Visser; Richard A Hughes
Journal:  Neuromuscul Disord       Date:  2004-05       Impact factor: 4.296

2.  A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy.

Authors:  Lisa Christopher-Stine; Livia A Casciola-Rosen; Grace Hong; Tae Chung; Andrea M Corse; Andrew L Mammen
Journal:  Arthritis Rheum       Date:  2010-09

3.  Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series.

Authors:  Ritu Valiyil; Livia Casciola-Rosen; Grace Hong; Andrew Mammen; Lisa Christopher-Stine
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-09       Impact factor: 4.794

4.  205th ENMC International Workshop: Pathology diagnosis of idiopathic inflammatory myopathies part II 28-30 March 2014, Naarden, The Netherlands.

Authors:  Jan L De Bleecker; Boel De Paepe; Eleonora Aronica; Marianne de Visser; Anthony Amato; Eleonora Aronica; Olivier Benveniste; Jan De Bleecker; Onno de Boer; Boel De Paepe; Marianne de Visser; Mazen Dimachkie; Romain Gherardi; Hans Hilmar Goebel; David Hilton-Jones; Janice Holton; Ingrid E Lundberg; Andrew Mammen; Frank Mastaglia; Ichizo Nishino; Elisabeth Rushing; Henrik Daa Schroder; Duygu Selcen; Werner Stenzel
Journal:  Neuromuscul Disord       Date:  2014-12-10       Impact factor: 4.296

Review 5.  Diagnosis and Management of Immune-Mediated Myopathies.

Authors:  Margherita Milone
Journal:  Mayo Clin Proc       Date:  2017-05       Impact factor: 7.616

Review 6.  Classification and management of adult inflammatory myopathies.

Authors:  Albert Selva-O'Callaghan; Iago Pinal-Fernandez; Ernesto Trallero-Araguás; José César Milisenda; Josep Maria Grau-Junyent; Andrew L Mammen
Journal:  Lancet Neurol       Date:  2018-09       Impact factor: 44.182

Review 7.  Clinical cardiac involvement in idiopathic inflammatory myopathies: a systematic review.

Authors:  Raghav Gupta; Siddharth A Wayangankar; Ira N Targoff; Thomas A Hennebry
Journal:  Int J Cardiol       Date:  2010-09-09       Impact factor: 4.164

8.  Clinical Features and Treatment Outcomes of Necrotizing Autoimmune Myopathy.

Authors:  Charles D Kassardjian; Vanda A Lennon; Nora B Alfugham; Michael Mahler; Margherita Milone
Journal:  JAMA Neurol       Date:  2015-09       Impact factor: 18.302

9.  Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin.

Authors:  Yves Allenbach; Laurent Drouot; Aude Rigolet; Jean Luc Charuel; Fabienne Jouen; Norma B Romero; Thierry Maisonobe; Odile Dubourg; Anthony Behin; Pascal Laforet; Tania Stojkovic; Bruno Eymard; Nathalie Costedoat-Chalumeau; Emmanuelle Campana-Salort; Anne Tournadre; Lucile Musset; Brigitte Bader-Meunier; Isabelle Kone-Paut; Jean Sibilia; Laurent Servais; Olivier Fain; Claire Larroche; Elisabeth Diot; Benjamin Terrier; Raphael De Paz; Antoine Dossier; Dominique Menard; Chafika Morati; Marielle Roux; Xavier Ferrer; Jeremie Martinet; Sophie Besnard; Remi Bellance; Patrice Cacoub; Laurent Arnaud; Bernard Grosbois; Serge Herson; Olivier Boyer; Olivier Benveniste
Journal:  Medicine (Baltimore)       Date:  2014-05       Impact factor: 1.889

10.  2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups.

Authors:  Ingrid E Lundberg; Anna Tjärnlund; Matteo Bottai; Victoria P Werth; Clarissa Pilkington; Marianne de Visser; Lars Alfredsson; Anthony A Amato; Richard J Barohn; Matthew H Liang; Jasvinder A Singh; Rohit Aggarwal; Snjolaug Arnardottir; Hector Chinoy; Robert G Cooper; Katalin Dankó; Mazen M Dimachkie; Brian M Feldman; Ignacio Garcia-De La Torre; Patrick Gordon; Taichi Hayashi; James D Katz; Hitoshi Kohsaka; Peter A Lachenbruch; Bianca A Lang; Yuhui Li; Chester V Oddis; Marzena Olesinska; Ann M Reed; Lidia Rutkowska-Sak; Helga Sanner; Albert Selva-O'Callaghan; Yeong-Wook Song; Jiri Vencovsky; Steven R Ytterberg; Frederick W Miller; Lisa G Rider
Journal:  Arthritis Rheumatol       Date:  2017-10-27       Impact factor: 10.995

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.